Somatic hypermutation shapes the viral escape profile of SARS-CoV-2 neutralising antibodiesResearch in context
Summary: Background: Since the onset of the COVID-19 pandemic, SARS-CoV-2 neutralising monoclonal antibodies (mAbs) are being developed for clinical use. With the appearance of new virus variants, most mAbs lost their virus-neutralising activity, highlighting the complexity of mAb development under...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2025-06-01
|
| Serija: | EBioMedicine |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S2352396425002142 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
